Neurosarcoidosis has a heterogeneous presentation, often with a delay in diagnosis. We aimed to clarify the clinical features, investigation results and factors predicting outcome of patients with neurosarcoidosis.Methods
We retrospectively analysed the clinical records of all patients diagnosed with neurosarcoidosis at our hospital between 2010 and 2015.Results
24 patients were diagnosed with neurosarcoidosis during this period. Presentation varied widely and 25% of cases had no other organs affected by sarcoidosis at diagnosis. Serum and CSF ACE levels were not raised in most patients (55% and 55.56% respectively of those patients tested). 80.95% of patients had a good outcome (modified Rankin score 0–2) at 12 months after diagnosis. Patients with widespread CNS disease at presentation were more likely to have a poor outcome when compared with patients with limited involvement (mean Rankin score: 4 vs 0.89 at 12 months, p-0.009). CSF oligoclonal bands were also more likely to be raised in patients who had a poor outcome at 12 months (mean Rankin score: 2.29 vs 1.88, p 0.0966).Conclusion
These results suggest it might be possible to risk stratify patients which may prompt earlier immunomodulatory therapy. Research with a larger cohort of patients may help to clarify this.